New antibody drug shows promise for kidney disease
Disease control
Completed
This Phase 2 trial tested a drug called felzartamab in 54 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The drug targets immune cells to reduce protein leakage in urine, a sign of kidney damage. The study compared felzartamab to a placebo to see i…
Phase: PHASE2 • Sponsor: HI-Bio, A Biogen Company • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC